Adyen N.V. : The upward trend should continue
BUY
Repli_rebond
Stop-loss triggered
Entry price | Target | Stop-loss | Potential |
---|
€850 |
€950 |
€810 |
+11.76% |
---|
Shares in Adyen N.V. have recently benefitted from a regain of interest by market participants. The technical chart pattern suggests a continuation of the upward movement.
Strengths● The prospective high growth for the next fiscal years is among the main assets of the company
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● The stock is in a well-established, long-term rising trend above the technical support level at 742.6 EUR
Weaknesses● The company's "enterprise value to sales" ratio is among the highest in the world.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 131.35 times its estimated earnings per share for the ongoing year.
● The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.